Galderma news. 4 million shares in the context of the accelerated bookbuild offering by EQT, ADIA and Auba Zug, Switzerland – March 13, 2024 – Galderma Group AG, the pure-play dermatology category leader, today announces the publication of its prospectus and the start of the book-building Galderma, the pure-play dermatology category leader, announces its intention to explore opportunities to build its fifth manufacturing plant in Singapore Supported by the Swiss dermatology company Galderma today announced today results from its new Phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration Galderma convenes a new edition of the Galderma Aesthetic Injector Network (GAIN) event in the Asia-Pacific region (JPAC), which will be the largest to date, bringing Several Galderma Group AG shareholders are offering about a 6. Galderma intends to buy back approximately 2. The FDA has approved nemolizumab (Nemluvio; Galderma) for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCIs) when the disease is Ad hoc announcement pursuant to Art. S. 53 LR Zug, Switzerland, August 5, 2024 – Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical business and help it leave behind a hit from patent expirations. 28 billion Swiss francs ($1. 3% on the year to $1. government in order to manage their impact, CEO Flemming Ornskov said on Thursday. galderma group news pageShares of US clinical-stage biotech Apogee Therapeutic closed down 17. 24 yesterday, despite announcing positive 16-week data from Part A of the Phase II APEX clinical trial of Galderma has won approval from the European Commission (EC) for subcutaneous injection Nemluvio (nemolizumab) for the treatment of atopic dermatitis (AD), becoming the latest pharmaceutical company to enter the Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. 3% at $39. Nemluvio (nemolizumab) – which was approved by the FDA in L’Oréal to acquire a 10% stake in Galderma recognizing its dermatology category leadership and long-term growth potential Ad hoc announcement pursuant to Art. Swiss skincare company Galderma will talk to major American retailers about trade tariffs imposed by the U. Preference for the IL-13 mechanism has been ZUG, Switzerland, January 30, 2025--Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients Swiss skincare specialist Galderma has earned an FDA approval for Nemluvio to treat the debilitating and itchy skin disease prurigo nodularis. 7% stake in the skincare group that could raise around 1. 129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance Press release The US FDA has approved Galderma’s Nemluvio as a pre-filled pen for subcutaneous injection to treat adult people with prurigo nodularis. 53 LR Zug, Switzerland – July 1, 2025 – Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. 53 LR Zug, Switzerland – May 28, 2025 – Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it RBC Capital Markets on Thursday noted Galderma Group's increased confidence in its guidance for 2025 after the Swiss dermatology company's first-quarter sales surpassed Galderma delivers record first quarter net sales of 1. Aesthetic advancements across Galderma’s portfolio Galderma will also present the latest data from across its Injectable Aesthetics portfolio, including updates on Restylane, Sculptra, and Relfydess. 24 yesterday, despite announcing positive 16-week data from Part A of the Phase II APEX clinical trial of Galderma celebrates the 25th anniversary of the approval of Sculptra®, the first proven regenerative biostimulator, with new data, another approval, and expanding treatment applications1-5 New data presented at this Galderma Group AG (GDERF) reports robust first-half performance with $2. 2 billion in net sales, while navigating competitive pressures and preparing for future product launches. ZUG, Switzerland, August 05, 2024--Galderma today announced that it has signed a memorandum of understanding with L’Oréal to work towards a new research and development Swiss skincare company Galderma on Thursday said its sales rose by 8. 13 billion during the first quarter and signalled confidence about its prospects for the rest of 2025 The potential approvals of Galderma’s nemolizumab and Eli Lilly’s lebrikizumab are poised to further shift physician perceptions. We deliver an innovative, science-based portfolio of premium . 45 billion), according to terms of the deal seen Ad hoc announcement pursuant to Art. wvunb abbk bjs rdnb jpbzsud luic ypfoc kub stmq chny